BioCentury | Nov 6, 2020
Regulation

Nov. 5 Quick Takes: Setback for bluebird sinks shares; plus Cellectis, CRISPR, REMS, Novocure

...College and Sassoon General Hospital reported the data in medRxiv.Novocure prices $500M note deal Oncology company Novocure Ltd....
...$75 million in notes. BC Staff Zynteglo (LentiGlobin BB305 gene therapy, Betibeglogene autotemcel) bluebird bio CRISPR Therapeutics AG AstraZeneca plc Cellectis S.A. Novocure Ltd. U.S...
BioCentury | Sep 16, 2020
Finance

Zai aiming to gain dual listing via Hong Kong offering

...alternating electric fields and is marketed by Novocure Ltd....
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...company in February after the company’s fiscal 2Q earnings disappointed.Mike Ambrogi stepped down as COO of Novocure Ltd....
...succeeded in his role by Ashley Cordova. She was SVP of finance and investor relations. Novocure...
...named Wassim Fares as CMO. He was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf...
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

...Again, only two companies posted market cap declines, with the biggest, an 11% decline by NovoCure Ltd....
...Analytics INO-4800 NVX-CoV2373 sarizotan (EMD-128130) NC318 NC410 Tepezza, teprotumumab (HZN-001, RV001, r1507, rg1507) Moderna Inc. Horizon Therapeutics plc Inovio Pharmaceuticals Inc. Novavax Inc. Celldex Therapeutics Inc. Biogen Inc. Novocure Ltd. NextCure...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...which uses Tumor Treating Fields technology that delivers alternating electric fields and is marketed by Novocure Ltd....
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...dyskinesia. China is the second country after the U.S. to have approved the therapy. Zai, Novocure...
...Optune plus temozolomide to treat newly diagnosed glioblastoma and as monotherapy to treat recurrent GBM. Novocure Ltd....
BioCentury | Apr 8, 2020
Deals

Zai adds second bispecific to pipeline via Regeneron deal

...Optune, which uses Tumor Treating Fields technology that delivers alternating electric fields, is marketed by Novocure Ltd....
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...hired Peter Melnyk as CEO and Ernest De Paolantonio as CFO. Melnyk was CCO at Novocure...
BioCentury | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

...Zejula niraparib from Tesaro Inc., now part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); and Optune from Novocure Ltd....
BioCentury | May 24, 2019
Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

...Genfit's Phase III RESOLVE-IT trial of elafibranor to treat NASH. Novocure's NovoTTF-100L gets U.S. approval Novocure Ltd....
...Other), Jakafi (Other) lanifibranor (iva337) NovoTTF-100L, Tumor Treating Fields (TTFields) Alpine Immune Sciences Inc. Genfit S.A. Gilead Sciences Inc. Incyte Corp. Inventiva S.A. Novocure Ltd....
Items per page:
1 - 10 of 79
BioCentury | Nov 6, 2020
Regulation

Nov. 5 Quick Takes: Setback for bluebird sinks shares; plus Cellectis, CRISPR, REMS, Novocure

...College and Sassoon General Hospital reported the data in medRxiv.Novocure prices $500M note deal Oncology company Novocure Ltd....
...$75 million in notes. BC Staff Zynteglo (LentiGlobin BB305 gene therapy, Betibeglogene autotemcel) bluebird bio CRISPR Therapeutics AG AstraZeneca plc Cellectis S.A. Novocure Ltd. U.S...
BioCentury | Sep 16, 2020
Finance

Zai aiming to gain dual listing via Hong Kong offering

...alternating electric fields and is marketed by Novocure Ltd....
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...company in February after the company’s fiscal 2Q earnings disappointed.Mike Ambrogi stepped down as COO of Novocure Ltd....
...succeeded in his role by Ashley Cordova. She was SVP of finance and investor relations. Novocure...
...named Wassim Fares as CMO. He was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf...
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

...Again, only two companies posted market cap declines, with the biggest, an 11% decline by NovoCure Ltd....
...Analytics INO-4800 NVX-CoV2373 sarizotan (EMD-128130) NC318 NC410 Tepezza, teprotumumab (HZN-001, RV001, r1507, rg1507) Moderna Inc. Horizon Therapeutics plc Inovio Pharmaceuticals Inc. Novavax Inc. Celldex Therapeutics Inc. Biogen Inc. Novocure Ltd. NextCure...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...which uses Tumor Treating Fields technology that delivers alternating electric fields and is marketed by Novocure Ltd....
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...dyskinesia. China is the second country after the U.S. to have approved the therapy. Zai, Novocure...
...Optune plus temozolomide to treat newly diagnosed glioblastoma and as monotherapy to treat recurrent GBM. Novocure Ltd....
BioCentury | Apr 8, 2020
Deals

Zai adds second bispecific to pipeline via Regeneron deal

...Optune, which uses Tumor Treating Fields technology that delivers alternating electric fields, is marketed by Novocure Ltd....
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...hired Peter Melnyk as CEO and Ernest De Paolantonio as CFO. Melnyk was CCO at Novocure...
BioCentury | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

...Zejula niraparib from Tesaro Inc., now part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); and Optune from Novocure Ltd....
BioCentury | May 24, 2019
Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

...Genfit's Phase III RESOLVE-IT trial of elafibranor to treat NASH. Novocure's NovoTTF-100L gets U.S. approval Novocure Ltd....
...Other), Jakafi (Other) lanifibranor (iva337) NovoTTF-100L, Tumor Treating Fields (TTFields) Alpine Immune Sciences Inc. Genfit S.A. Gilead Sciences Inc. Incyte Corp. Inventiva S.A. Novocure Ltd....
Items per page:
1 - 10 of 79